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Heat shock proteins (HSPs), also known as “stress pro-
teins,” are among the highly conserved and immunogenic
proteins shared among diverse groups of microbial agents
and mammals [1]. Heat and other types of stressful stimuli
can increase the cellular expression of HSPs. These proteins
have been categorized into different families according to
their molecular mass, for example, HSP110, HSP90, HSP70,
HSP60, HSP40, HSP20-30, and HSP10 [1–3]. For uniformity,
guidelines for the nomenclature of various humanHSP fami-
lies have been proposed [4]. Under physiological conditions,
the ubiquitously distributed HSPs maintain the integrity and
function of other cellular proteins in stressful conditions.
However, HSPs also can become targets of immune response,
resulting in immune pathology and clinical manifestations of
autoimmunity. HSPs have been implicated in the pathogene-
sis of a variety of autoimmune diseases [3, 5–7]. Moreover,
the involvement of other small HSPs (e.g., H11/HspB8)
besides the canonical members of that family in health and
disease is increasingly being realized. Importantly, HSPs
are also capable of inducing immune responses that are
immunoregulatory in nature [7–10], including resolution of
the inflammatory responses [11]. Also, the concept of immune
network (immunological homunculus) including HSPs as
one of its components has been proposed to explain immune
homeostasis in health and disease [12].
The main focus of this special issue is on the role
of different HSPs in the pathogenesis of autoimmunity
through induction/propagation as well as regulation of the
disease-related processes; on the impact of physiological and
disease-relatedmetabolic processes on the induction ofHSPs;
on the mechanistic basis of the effector functions driven
by HSPs; and on the immunomodulatory role of HSPs.
Thirteen excellent papers describing new original results and
the most recent developments in the field on these topics
are presented in this special issue. These papers cover the
role of HSPs in antigen cross-presentation, induction of
autoimmunity, and immunotherapy of autoimmunity/cancer
(R. Binder et al., Y. Kato et al., and S. Calderwood et al.);
the role of HSPs in the pathogenesis of the autoimmune
components of diverse diseases including atherosclerosis
(A. Kilic and K. Mandal); systemic lupus erythematosus
(H. Shukla and P. Pitha); Behcet’s disease (J. Shimizu et al.),
uveitis (A. Commodaro et al.), and diabetes (C. Blasi et al.);
the relationship between infection, particularly M. paratu-
berculosis, and autoimmunity (C. Dow); the role of small
heat-shock protein H11/HspB8 and its homologous proteins
in human disease (L. Aurelian et al.); the impact of exercise
and metabolic disorders on HSPs (E. Noble and G. Shen);
the immunosuppressive activity of HSP70 (P. Stocki and A.
Dickinson); and HSP-induced regulatory T cells and their
role in control of autoimmunity (E. Brenu et al.).These papers
highlight results obtained from studies in animal models as
well as patients with autoimmune or metabolic disorders.
HSPs are highly conserved in nature, and they are
also quite immunogenic. These attributes may render these
proteins as initiators of immune response as well as targets
of autoimmune attack. Foreign (e.g., microbial) HSPs may
prime cellular or humoral immune responses that might
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be cross-reactive with the corresponding self-HSPs or other
self-antigens leading to the induction of autoimmunity.
“Molecular mimicry” and unveiling of the previously cryptic
(hidden) determinants are among the different mechanisms
involved in the induction of autoimmunity [3]. Interestingly,
foreign-self mimicry may not always be pathogenic; instead,
it may be immunoregulatory in nature [13, 14]. Further,
defined pathogenic versus regulatory T- or B-cell epitopes
have been identified within the same HSP, for example
HSP60/65. Accordingly, during the course of autoimmunity,
epitope spreading or diversification of response can lead to
induction of new T-cell/antibody responses, which in turn
may aggravate or downmodulate autoimmunity depending
on the antigenic epitopes targeted in the process. Several
papers in this special issue discuss the pathogenic role
of HSP-induced immunity. The role of particular HSPs in
specific autoimmune disorders is highlighted in the papers
on atherosclerosis (A. Kilic and K. Mandal), uveitis (A.
Commodaro), lupus (H. Shukla and P. Pitha), and Behcet’s
disease (J. Shimizu et al.). A viewpoint on the role of M.
paratuberculosisHSP65 in the induction of autoimmunity via
molecular mimicry is presented by C. Dow. Two papers in
this issue have addressed the relationship between HSPs and
metabolic disorders with components of autoimmunity (E.
Noble and G. Shen; C. Blasi et al.).
HSPs are known to play critical roles in innate immunity
as well as adaptive immunity. HSPs can activate specific toll-
like receptors (TLRs) and influence activation of antigen-
presenting cells (APC) and thereby other immune cells
including T cells and B cells. These proteins also play a major
role in cross-presentation of extracellular antigens such as
microbial antigens or tumor antigens in parenchymal cells via
the class I pathway resulting in induction of CD8+ cytotoxic
T-lymphocyte (CTL) responses [15, 16]. Cross-presentation of
HSP-mediated presentation of self-antigens might also play a
role in the pathogenesis of autoimmunity. The mechanistic
basis of the role of HSPs in cross-presentation of antigens
and the impact of this process on immune response in cancer
and autoimmunity are elaborated in this issue in papers by S.
Calderwood et al., R. Binder et al., and Y. Kato et al.
HSPs are induced by a variety of stressful stimuli, and
they aid in controlling the physical and metabolic integrity
of the cells under stress. Metabolic disorders and exercise can
induce HSPs and activate other heat-shock factor-1- (HSF-1-)
mediated effector pathways. These in turn can enhance the
generation of mediators of inflammation. E. Noble and G.
Shen discuss in this issue the above-mentioned associations,
including their dual role in inflammation. However, C. Blasi
et al. report that an effective control of type 2 diabetes was
not accompanied by a reduction in serum levels of HSP60
and antibodies to HSP60, while it lowered the levels of the
proinflammatory cytokine IL-6.
As elaborated above, HSPs are involved in the induction
as well as regulation of immune responses. How the same
proteins can mediate opposite outcomes is a dilemma for
both basic researchers and physician investigators. This dual
role of HSPs has been revealed in a wide variety of disorders,
including autoimmune diseases and tumors, as well as in
immune responses associated with organ transplantation
[7, 8, 10, 13, 15, 17, 18]. It is becoming clear that the pro-
versus anti-inflammatory activities of HSPs are contextual
and affected by multiple factors including the concentration
of HSP, the timing of exposure to HSP, and the overall
physiopathological milieu at the target site. Another chal-
lenge regarding HSPs and immune responses lies in the
fact that autoimmunity and tumors present with opposite
requirements for control of the disease processes [2, 17].
Autoimmunity involves a breakdown of self-tolerance and
induction of anti-self immune responses. Accordingly, an
effective control of autoimmunity requires suppression of
autoreactive immune responses. On the contrary, tumors
survive and grow in the body owing to an ineffective antitu-
mor response in part because of immune-evasive strategies
adopted by tumor cells. A deliberate induction of potent
antitumor immunity is required to control cancer. HSPs are
being exploited differentially to control autoimmunity and
cancer. The disparate roles of HSPs in tumor immunity and
autoimmunity and the molecular and cellular mechanisms
involved therein are discussed here by S. Calderwood et al.,
R. Binder et al., and L. Aurelian et al.
HSPsmay facilitate regulation of effector responses under
appropriate conditions [3, 7–9]. This can be achieved in part
via increasing the production of anti-inflammatory cytokines
so as to deviate the cytokine balance from a proinflammatory
to an anti-inflammatory type. In addition, HSPs may induce
different types of regulatory T cells, including CD4+ Tr1
cells that secrete interleukin-10 (IL-10) and CD4+CD25+
Forkhead-box-P3- (Foxp3-) expressing Treg that produce
transforming growth factor-b (TGF-𝛽) and IL-10. Treg may
alsomediate their effect via cell-to-cell contact with the target
cells. In this issue, the immunosuppressive activity of HSP is
outlined by P. Stocki and A. Dickinson, while HSP-induced
regulatory cells are described by E. Brenu et al.
HSPs are being exploited for immunotherapy of autoim-
mune diseases and cancer [2, 15, 19, 20]. The current
approaches under development or those being tested in clin-
ical trials harness the immunoregulatory properties of HSPs.
For example, purified HSPs or their peptides containing
defined epitopes are being tested in clinical trials in type 1
diabetes [19] and rheumatoid arthritis [20] patients with the
hope of developing immunotherapeutic approaches for these
debilitating diseases. The use of HSP-induced regulatory T
cells is an emerging area of potential promise in this regard
[9].
We hope you enjoy reading the diverse collection of
outstanding papers in this special issue.
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